PubMed Health⌕ Search

Biomedical subjects

C Doutremepuich

Publications and source records attributed to C Doutremepuich.

At least 73 records · Page 4Linked to original sources
PubMed1989

[Low molecular weight heparins].

The apparition in the 80's of low molecular weight heparins (LMWHs) obtained by chemical or enzymatical splitting, modified the fields of prophylactic treatment of thromboembolic diseases. These drugs present on heparin numerous advantages: equal antithrombotic activity with a smaller bleeding risk, higher bioavailability, longer pharmacokinetic, which simplify their use. The definite mode of action remains unknown, but LMWH act at different steps like coagulation (by AT III), fibrinolysis, blood cells, endothelial cells. Further, like heparin, they can be neutralized by protamine. However the right, simple, specific biological assay which presents a good correlation with the antithrombotic activity, remained to be established.

Heparin, Low-Molecular-Weight↗
PubMed1988

[Low-molecular weight heparins in post-surgical recovery].

Low molecular weight heparins are used in human therapy for preventing venous thrombosis during the postoperative period. The monitoring of this therapy uses a measurement of the factor Xla activity. A value of this activity higher than 0.4 IU/ml, suggests a hemorrhage risk. The use of these low molecular weight heparins for the treatment of venous thrombosis is now under investigation. However, the biological monitoring of this treatment has not yet been defined. The anti IIa and anti Xa activities seem to be interesting. In fact the antithrombotic power would be due to the anti IIa and profibrinolytic activities.

Animals↗
PubMed1987

Influence of heparin and a low molecular weight heparin fraction of the leukocytes in an experimental venous thrombosis model.

A randomized study was performed to observe the effects induced by heparin and a low molecular weight heparin fraction (at different dosages) on the leukocytes of rats in the presence of experimental venous thrombosis. The experimentation was carried out on two series of animals: the first with a ligature of the inferior vena cava inducing the formation of a thrombus, the second without any ligature. The results show that the induction of thrombosis involves: in the blood, an increase of the number leukocytes, principally polymorphonuclear cells; in the thrombi, a significant rise in the total count of leukocytes, here mononuclear cells; the latter number increases with the dosages of the administered drugs.

Animals↗
PubMed1985

[Passage of commercial heparin and a low molecular weight fragment of heparin, CY 222, across the placenta of pregnant rabbits].

Because of a further clinical use of low-molecular weight heparin fraction in prevention or treatment of venous thrombo-embolism, it was necessary to establish whether they cross the placenta. The studies were performed in pregnant rabbits. High doses of commercial unfractionated heparin (1 000 and 1 600 anti-Xa units per kg of body-weight) and high doses of a low molecular weight heparin fraction (1 000; 8 000 and 16 000 anti-Xa units per kg of body weight) were injected to animals at the end of gestation (term: 30 days). The placenta crossing was studied by drawing blood samples from the mother and foetus for assays of heparin blood level. There is no detectable levels of heparin in the foetus at any time after injection of commercial heparin at the dose of 1 000 anti-Xa units per kg; meanwhile heparin blood level is very low at the dose of 16 000 anti-Xa units/kg. The low molecular weight heparin fraction do not cross the placenta at the dose of 1 000 anti-Xa units/kg. However for higher doses (8 000 and 16 000 anti-Xa/kg) this heparin fraction gives a foetal heparin blood level upper than the one given by commercial heparin.

Animals↗